MAP2K7 and head and neck squamous cell carcinoma: Furthermore, our experimental data revealed that PD-901, a MEK1/2 inhibitor, increases sensitivity of HNSCC cell lines to cetuximab and fractionated-IR, providing potential clinical benefit from a combination of MEK inhibitor with clinically available cetuximab treatment and radiotherapy.